stockrow
Friday 6 November 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
- Revenue
- −98.4%
- EPS
- +80.9%
- Free cash flow
- −5.22%
Quarter to September 2026, against a year earlier
0.52
0.02
+4.00%
Follow APRE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(79.37%) | (41.85%) | (47.44%) | (62.83%) | |
| (63.14%) | (35.25%) | (41.30%) | (53.24%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(98.00%) | (28.46%) | (31.65%) | (40.97%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(1.97) | (0.82) | (0.23) | (0.24) | |
Free Cash Flow |
(12.89) | (12.02) | (12.19) | (12.74) | |
Capital Expenditures |
— | — | (0.02) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(47.68%) | (13.65%) | (15.30%) | (17.70%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,465.17% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2,266.92% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
167.34% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.02 | 1.01 | 0.99 | 0.90 | |
Depreciation/Fixed assets |
0.36 | 0.40 | 0.34 | 0.36 | |
Capex/Depreciation |
0.00 | 0.00 | (1.04) | (0.68) | |
Revenue per Share |
0.04 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.97) | (0.82) | (0.23) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026